---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-157521"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2024-06-07T23:59:59+00:00"
generated_at: "2026-06-01T05:36:13.364900+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# 4D Molecular Therapeutics enters $250M ATM equity distribution agreement with Leerink Partners

## Summary
- Company enters Sales Agreement to sell up to $250M common stock via at-the-market offering through Leerink Partners.
- Agent compensation up to 3.0% of gross proceeds; sales made on Nasdaq via Rule 415(a)(4).
- Offering registered under existing S-3 filed Feb 2024; prospectus supplement filed June 7, 2024.
- No minimum sales obligation; company may terminate at any time upon prior notice.
- Proceeds for general corporate purposes; no escrow arrangement.

## SEC filing metadata
- accession: 0001193125-24-157521
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2024-06-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000119312524157521/0001193125-24-157521-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000119312524157521/d835355d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-157521
- JSON: https://secwatch.observer/filing/0001193125-24-157521.json
- Plain text: https://secwatch.observer/filing/0001193125-24-157521.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.